MediWound Ltd.

NasdaqGM MDWD

MediWound Ltd. EBITDA for the year ending December 31, 2023: USD -4.89 M

MediWound Ltd. EBITDA is USD -4.89 M for the year ending December 31, 2023, a 72.95% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

MediWound Ltd. EBITDA for the year ending December 31, 2022 was USD -18.09 M, a -61.20% change year over year.
MediWound Ltd. EBITDA for the year ending December 31, 2021 was USD -11.22 M, a -44.79% change year over year.
MediWound Ltd. EBITDA for the year ending December 31, 2020 was USD -7.75 M, a -326.41% change year over year.
MediWound Ltd. EBITDA for the year ending December 31, 2019 was USD 3.42 M, a 167.28% change year over year.

Key data

Date	EBITDA	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)

NasdaqGM: MDWD

MediWound Ltd.

CEO	Mr. Ofer Gonen B.Sc.
IPO Date	March 20, 2014
Location	Israel
Headquarters	42 Hayarkon Street
Employees	100
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.

Key trends

Past 5 years